Ospemifene, vulvovaginal atrophy, and breast cancer

Gregory T. Wurz, Lin H. Soe, Michael W. DeGregorio

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted.

Original languageEnglish (US)
Pages (from-to)220-225
Number of pages6
Issue number3
StatePublished - Mar 2013


  • Antiestrogen
  • Breast cancer
  • Ospemifene
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Ospemifene, vulvovaginal atrophy, and breast cancer'. Together they form a unique fingerprint.

Cite this